Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.22.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 27 Months Ended
Jul. 01, 2021
Mar. 31, 2022
Mar. 31, 2021
Sep. 30, 2022
Mar. 31, 2022
Dec. 31, 2024
Disaggregation of Revenue [Line Items]            
Total revenue   $ 1,173 $ 473      
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio            
Disaggregation of Revenue [Line Items]            
Amount received   2,200        
Other long-term debt   2,000     $ 2,000  
Other receivables   1,000     $ 1,000  
Forecast | Discontinued Operations, Disposed of by Sale | Pediatric Portfolio            
Disaggregation of Revenue [Line Items]            
Proceeds from divestiture of businesses       $ 2,000   $ 1,000
Product Revenue            
Disaggregation of Revenue [Line Items]            
Total revenue   1,173 $ 473      
Millipred | Teva            
Disaggregation of Revenue [Line Items]            
Percent of net profit for installment payments         50.00%  
Installment payment $ 500          
Royalty expense   $ 600        
Sales Revenue | Customer Concentration Risk | Major Customer Number One            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage   75.00%        
Sales Revenue | Customer Concentration Risk | Major Customer Number Two            
Disaggregation of Revenue [Line Items]            
Concentration risk percentage   25.00%